The current study is a phase II multi-center single arm trial to evaluate the efficacy and
safety of adding Anti-PD-1 antibody in an inductive and concurrent way to radiotherapy in
early-stage low-risk extranodal NK/T cell lymphoma, nasal type
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University Beijing Cancer Hospital First Affiliated Hospital of Jilin University